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Squamous cell carcinoma of the lung (SQCLC) is generally associ-
ated with smoking and is preceded by clinically and histologically
definable preinvasive lesions of the bronchial epithelium (Auerbach
et al, 1957, 1962, 1979). Squamous cell metaplasia, developing
from basal cell hyperplasia, is the earliest recognizable morpho-
logical, but not yet neoplastic, change. Mild, moderate and severe
dysplasias and squamous cell carcinoma in situ are already prema-
lignant, but still non-invasive lesions (World Health Organization,
1981). The malignant phenotype of invasive carcinoma is believed
to develop as a result of aberrations in the expression and function of
oncogenes, proto-oncogenes and tumour-suppressor genes (e.g. bcl-
2 and p53), leading to a growth advantage of the neoplastic cells.
p53 and the genes of the bcl-2 family, such as bcl-2, bax and mcl-1,
are regulatory genes of apoptosis, an event in which single cells die
following a highly defined, predetermined programme. During this
event, several morphological changes lead to the formation of
membrane-bound apoptotic bodies, which are then phagocytosed by
neighbouring cells (Kerr et al, 1972).
Mutations in the p53 tumour-suppressor gene are found in 37%
of all human malignancies and in 60% of lung carcinomas
(Greenblatt et al, 1994). Aberrant expression of p53 has also been
detected in preinvasive lesions of the bronchial epithelium (Sozzi
et al, 1992; Sundaresan et al, 1992; Vähäkangas et al, 1992;
Bennett et al, 1993; Nuorva et al, 1993; Hirano et al, 1994; Walker
et al, 1994), in which it is associated with the severity of dysplasia
(Sundaresan et al, 1992; Bennett et al, 1993; Nuorva et al, 1993;
Hirano et al, 1994; Walker et al, 1994).
The effects of the ever-expanding bcl-2 gene family on apop-
tosis are under intensive research. The first member of this group
was the bcl-2 proto-oncogene, which was first identified in follic-
ular lymphomas (Tsujimoto et al, 1984; Bakhshi et al, 1985) and
was later found to be an inhibitor of apoptosis induced by a wide
variety of stimuli (Reed, 1994). In normal skin, bcl-2 is expressed
in the basal epithelial cells (Hockenbery et al, 1991; Lu et al,
1993). In bronchial dysplasias, bcl-2 expression can be detected
throughout the epithelial layer, and the irregularity of the staining
pattern increases concurrently with the degree of dysplasia
(Walker et al, 1995). bax, a member of the bcl-2 gene family,
produces a protein with approximately 21% amino acid sequence
homology with bcl-2 (Oltvai et al, 1993). When overexpressed,
bax forms homodimers and a cell death-promoting signal is accel-
erated. In contrast, when bcl-2 is in excess, it heterodimerizes with
bax and cell death is repressed (Oltvai et al, 1993). Thus, it has
been suggested that the ratio of bcl-2 to bax determines the suscep-
tibility of a cell to apoptosis (Oltvai et al, 1993). Mcl-1, which
displays functional similarity to bcl-2, is capable of binding to bax
and suppressing bax-induced cytotoxicity (Bodrug et al, 1995).
Recently, it was shown that members of the bcl-2 family regu-
late apoptosis through their ability to alter the mitochondrial
membrane potential and to form ion channels (Kroemer, 1997;
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Minn et al, 1997; Yang et al, 1997). This leads to the liberation of
caspase-activating substances, such as cytochrome c (CK) and
apoptosis-inducing factor (AIF), from the mitochondria into the
cytosol causing apoptosis of the cell. The proapoptotic bax has
been shown to induce the liberation of such caspase-activating
substances, whereas the antiapoptotic bcl-2 and bcl-xL inhibit it
(Kroemer, 1997; Minn et al, 1997; Yang et al, 1997).
A high level of apoptotic activity in tumours is generally
considered to signify slower tumour growth and a better prognosis.
In our previous work, however, enhanced apoptosis in non-small-
cell lung carcinoma (NSCLC) was associated with shortened
survival (Törmänen et al, 1995). In addition, the relative number
of apoptotic cells and bodies was independent of the expression of
p53 and bcl-2 (Törmänen et al, 1995). In human colorectal tubular
adenomas, apoptotic cells are seen more frequently in high- than in
low-grade dysplasias (Arai and Kino, 1995). In the light of these
observations, it was of interest to examine whether there is a trend
towards increased apoptosis in the premalignant lesions preceding
SQCLC and whether aberrations in the expression of apoptosis-
regulating genes, such as p53, bcl-2, bax and mcl-1, can already be
seen at this stage. We analysed the extent of apoptosis in 44
bronchial tissue samples representing normal bronchial epithe-
lium, squamous metaplasia, bronchial epithelial dysplasia and
carcinoma in situ.
MATERIALS AND METHODS
Case selection and classification of lesions
Forty-four formalin-fixed samples containing premalignant, non-
invasive, bronchial lesions were collected from the archives of the
Departments of Pathology, Oulu University Hospital, Finland, and
Central Finland Health Care District. All specimens were
histopathologically re-evaluated according to the World Health
Organization Histological Typing of Lung Tumours (1981), and
representative tissue samples were chosen for further studies. The
bronchial epithelium was normal in 14 cases, squamous metaplasia
was found in eight cases, mild epithelial dysplasia in three, moderate
dysplasia in eight and severe dysplasia in six cases. The lesions in
five samples were graded as squamous cell carcinoma in situ.
3¢ End labelling of apoptotic DNA fragments
Apoptotic cells and bodies in tissue sections were detected using
an ApopTag in situ Apoptosis Detection Kit (Oncor, Gaithersburg,
MD, USA). The instructions laid out by the manufacturer were
followed with a few modifications, as described previously
(Törmänen et al, 1995). A cell was defined as apoptotic if the
whole nuclear area was positively labelled, whereas apoptotic
bodies were identified as small, positively labelled, globular frag-
ments. All positively labelled cells and bodies fulfilled the
morphological criteria for apoptosis as described by Kerr et al
(1972), i.e. condensation of the nucleus, cell shrinkage, cyto-
plasmic budding to form membrane-bound fragments, and detach-
ment from surrounding cells.
The number of apoptotic cells and bodies in the epithelial tissue
was counted in ten high-power fields (HPFs; objective ´40, field
diameter 400 mm) when possible. In some specimens, the amount
of epithelium was not sufficient; in these cases, a minimum of four
HPFs were studied. Apoptotic bodies likely to be originating from
the same apoptotic cell were recorded as one apoptotic body. The
quantity of apoptotic cells and bodies, or apoptotic index (AI%), is
expressed as a percentage of the whole epithelial cell population.
Immunohistochemistry for p53
The immunohistochemistry for p53 was performed as described
previously by Törmänen et al (1995), using a polyclonal antibody
CM-1 (Novocastra Laboratories, Newcastle upon Tyne, UK) at a
dilution of 1:1000.
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Figure 1 The extent of apoptosis in normal bronchial epithelium and in the
metaplasia–dysplasia–carcinoma sequence of the bronchus. 3¢ End labelling
of apoptotic DNA. (A) One apoptotic cell (arrow) in normal bronchial
epithelium. (B) One apoptotic cell (arrow) in metaplastic epithelium. (C) Four
apoptotic bodies (arrows) in a moderately dysplastic area of the epithelium.
(D)Three apoptotic cells (arrows) in a squamous cell carcinoma in situ998 U Törmänen et al
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The cases were divided into six groups according to the
percentage of p53-positive nuclei in the whole epithelial layer as
follows: 0, negative; (+), <1% of positive nuclei; +, 1–5%; ++,
6–10%; +++, 11–40%; and ++++, >40% of positive nuclei.
Immunohistochemistry for proliferating cell nuclear
antigen (PCNA), bcl-2, bax and mcl-1
The procedure of bcl-2 immunohistochemistry using anti-human
bcl-2 antibody (clone 124, Dako, Glostrup, Denmark) is described
in our previous report (Törmänen et al, 1995). The immunohisto-
chemistry for PCNA, bax and mcl-1 was performed similarly
using the following antibodies: monoclonal anti-PCNA 19A2
(BioGenex, San Ramon, CA, USA) at a dilution of 1:20, incubated
30 min at room temperature; polyclonal anti-human bax
(Pharmingen, San Diego, CA, USA) at a dilution of 1:1000, incu-
bating overnight at room temperature; polyclonal anti-human
mcl-1 (Pharmingen) at a dilution of 1:1000, incubating overnight
at room temperature.
The positivity of bcl-2 was evaluated separately for the basal
epithelial layer and the other layers, and three groups were formed
based on the following classification: 0, negative; 1, positive only
in basal cell layer; and 2, positive in suprabasal epithelium. The
proliferative activity is defined as the percentage of PCNA-posi-
tive nuclei in the whole epithelial cell population. To describe the
expression of bax and mcl-1 in the bronchial epithelium, the inten-
sity of the immunostaining was evaluated as follows: 1, weak
cytoplasmic staining; 2, moderate cytoplasmic staining; 3, strong
cytoplasmic staining. Based on the quantity of the staining, the
specimens were divided into three groups: 1, 1–25% of positive
cells; 2, 26–50% of positive cells; 3, >50% of positive cells, for
bax or mcl-1. A combined index based on both the intensity and
the quantity of the immunostaining was determined by adding the
qualitative and the quantitative scores and, based on this, two
groups were formed: weak immunoreactivity (scores 0–4) and
strong immunoreactivity (scores 4–6).
Control stainings
A SQCLC previously shown to be p53 positive (Soini et al, 1992)
was used as a positive control for p53 immunostaining. A hyper-
plastic lymph node was used as a control for the labelling of
apoptotic DNA fragments and for bcl-2, PCNA, bax and mcl-1
immunohistochemistry. Negative controls for all immunostainings
were obtained by substituting the primary antibody with PBS.
Statistical analysis
The statistical analysis was performed with the SPSS for Windows
program package (Chicago, IL, USA). The values of the apoptotic
indices are reported as means with ranges. The significance of the
associations was determined by using the c2 test, Fisher’s exact
probability test, or Student’s two-tailed t-test. Probability values of
less than 0.05 were considered to be significant.
Table 1 The extent of apoptosis in normal and metaplastic bronchial epithelia, bronchial dysplasias and squamous cell carcinoma in situ of the lung
Apoptotic cells (%) Apoptotic bodies (%) Apoptotic index (%) Number of cases
mean (range) mean (range) mean (range) studied
Normal epithelium 0.18 (0.00–0.39) 0.16 (0.00–0.45) 0.34 (0.00–0.69) 14
Squamous metaplasia 0.34 (0.00–0.88) 0.59 (0.00–1.00) 0.92 (0.40–1.57) 8
Mild dysplasia 0.66 (0.27–1.11) 0.79 (0.41–1.13) 1.45 (0.68–1.94) 3
Moderate dysplasia 0.47 (0.00–1.11) 1.19 (0.09–3.60) 1.66 (0.18–4.40) 8
Severe dysplasia 0.64 (0.32–1.29) 0.73 (0.20–1.34) 1.37 (0.52–2.63) 6
Carcinoma in situ 0.51 (0.21–0.83) 0.98 (0.21–2.48) 1.49 (0.63–3.26) 5
Apoptotic indices were significantly higher in preinvasive bronchial lesions than in normal and metaplastic epithelia (P < 0.001).
Table 2 Distribution of p53 positivity in normal, metaplastic and dysplastic bronchial epithelia
Immunoreactivity for p53
Type of epithelium Negative <1% 1–5% 6–10% 11–40% >40% NA Total
Normal 14 14
Squamous cell metaplasia 7 1 8
Mild dysplasia 3 3
Moderate dysplasia 6 1 1 8
Severe dysplasia 4 2 6
Carcinoma in situ 211 1 5
Total number of sections 34 1 2 3 2 1 1 44
Abnormal accumulation of p53 protein (>1% of p53-positive nuclei) was more often observed in mild, moderate and severe dysplasias and carcinoma in situ
than in areas of normal and metaplastic epithelia (P < 0.001).Apoptosis in bronchial dysplasias 999
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RESULTS
Apoptosis in normal bronchial epithelium and
premalignant lesions
Bronchial epithelial cells in different stages of apoptosis could be
easily detected after 3¢ end labelling. Apoptotic cells, as well as
apoptotic bodies comprising small membrane-bound fragments
representing the last phase of apoptosis, were distributed
throughout the whole epithelial layer in all types of epithelium
studied (Figure 1A–D). The extent of apoptosis is presented in
Table 1. Interestingly, the mean apoptotic indices of the meta-
plastic epithelium were about threefold higher than those of the
normal bronchial epithelium. In mild and moderate dysplasias, the
apoptotic indices were over four times higher than normal epithe-
lium. When the samples were divided into two groups, the apop-
totic indices were significantly higher in premalignant lesions (i.e.
mild, moderate and severe dysplasias and carcinoma in situ) than
in normal and metaplastic bronchial epithelia (P = 0.001; Table 1).
Immunoreactivity of p53 and PCNA in normal bronchial
epithelium and preinvasive lesions
The distribution of p53 positivity is presented in Table 2. No posi-
tivity could be seen in normal epithelium. In dysplasias, p53-posi-
tive nuclei were mainly seen as groups throughout the epithelial
thickness. Abnormal accumulation of p53 protein (>1% of p53-
positive nuclei) was more often observed in mild, moderate and
severe dysplasias and in carcinoma in situ than in areas of normal
and metaplastic epithelia (P = 0.009; Table 2).
The extent of cell proliferation, as measured by PCNA immuno-
histochemistry, is shown in Table 3. PCNA-positive nuclei were
significantly more abundant in premalignant lesions than in
normal and metaplastic bronchial epithelia (P < 0.0001). p53-
positive nuclei were more frequently detected in areas in which
over 5% of the nuclei were positive for PCNA than in areas
presenting lower proliferation rates (P = 0.006; Table 4).
Expression of bcl-2, bax and mcl-1
A uniform cytoplasmic staining pattern was seen in bcl-2-positive
cells. In 13 samples of normal epithelium, bcl-2 positivity was
detected in the basal cell layer. In two cases of squamous cell
metaplasia, a positive reaction could be observed either in the
basal cell layer or in the suprabasal layers of the epithelium. bcl-2
positivity was seen throughout the whole epithelial thickness in 7
out of 21 cases of premalignant epithelial lesions, and only in the
basal cell layer in seven cases. Fourteen cases were negative for
bcl-2. Data could not be obtained in one case because of depletion
of tissue from the paraffin block.
Of the 18 cases showing strong immunoreactivity for bax (with
a combined score, based on both the intensity and the quantity of
the staining, higher than 4), ten were samples of normal or meta-
plastic bronchial epithelia, five were low-grade dysplasias (i.e.
mild or moderate) and three were high-grade dysplasias (i.e.
severe dysplasia or carcinoma in situ). Seventeen cases (eight
normal or metaplastic, four low-grade and five high-grade
dysplasias) showed strong immunoreactivity for mcl-1. No differ-
ences were found between the normal–metaplastic group and the
premalignant group in either bax or mcl-1 immunoreactivities.
Similarly, no correlation was found between the expression of bcl-
2 and bax when all the samples were evaluated as a single group or
in smaller groups.
Apoptosis in relation to p53, PCNA, bcl-2, bax and
mcl-1
The mean apoptotic indices of all the bronchial epithelial lesions
studied were higher in p53-positive than in p53-negative lesions
(P = 0.009; Table 5). However, no correlation between the extent
of apoptosis and positive p53 immunostaining was found when the
premalignant groups were evaluated separately (Table 5). A high
level of proliferative activity, as measured by PCNA immuno-
histochemistry, was associated with a higher apoptotic index (P =
0.012). No correlation was found between apoptotic activity and
the expression of bcl-2, bax and mcl-1 (Table 6).
Table 3 PCNA immunoreactivity
Percentage of PCNA-positive nuclei
Type of epithelium Mean Range Total number of sections
Normal 1 0–5 14
Squamous cell metaplasia 6 1–15 8
Mild dysplasia 24 8–40 3
Moderate dysplasia 10 5–20 8
Severe dysplasia 23 16–28 6
Carcinoma in situ 28 8–40 5
Table 4 p53 and PCNA immunoreactivity
PCNA immunoreactivity, number of cases
p53 status ≤5% Positive nuclei >5% Positive nuclei
Negative 17 9
Positive 0 6
p53-positive nuclei were more frequently detected in areas in which over 5%
of the nuclei were positive for PCNA than in areas of lower proliferation rate
(P = 0.006).1000 U Törmänen et al
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DISCUSSION
Apoptosis is one of the most actively studied phenomena in the
field of cell biology at the moment. There are several reports
describing its extent in neoplasias of different tissues, and most
indicate that apoptosis is more frequent in malignant than in
normal tissue (Lipponen and Aaltomaa, 1994; Aihara et al, 1995;
Arai and Kino, 1995; Bardeesy et al, 1995; Staunton and Gaffney,
1995; Törmänen et al, 1995; Soini et al, 1996). However, studies
of preneoplastic lesions are rare and, to our knowledge, none have
been published on bronchial dysplasias. The main purpose of the
present work was to study the extent of apoptosis in normal and
metaplastic bronchial epithelia and in non-invasive, premalignant
lesions preceding SQCLC, i.e. mild, moderate and severe
dysplasias and squamous cell carcinoma in situ.
We found the relative number of apoptotic cells and bodies
(apoptotic index) to increase as the normal epithelium of the
bronchus gradually alters to a premalignant lesion. In normal
epithelium, single cells undergoing apoptosis were seldom seen.
We assume that, in the normal epithelium, the apoptotic
programme functions normally, eliminating cells with a genetic
defect. Hence, an increased number of apoptotic cells and bodies
in metaplastic and dysplastic lesions might be the result of normal
activity, rather than of an impaired expression of apoptosis-
regulating genes, such as p53, thus reflecting a larger number
of damaged cells in the lesion.
In line with some previous studies, we found aberrant p53
expression to be associated with the severity of the dysplasia
(Sundaresan et al, 1992; Bennett et al, 1993; Nuorva et al, 1993;
Hirano et al, 1994; Walker et al, 1994). We also found the p53
protein to accumulate in lesions preceding SQCLC, starting with
mild dysplasia. The apoptosis-inducing function of p53 has been
thought to vanish whenever mutations occur (Lowe et al, 1994;
Bardeesy et al, 1995). This hypothesis is supported by the results
from Wilms’ tumours (Bardeesy et al, 1995) and small-cell lung
carcinomas (Eerola et al, 1997), in which there was an inverse
correlation between the extent of apoptosis and p53 mutations or
p53 immunoreactivity. In contrast, Lipponen and Aaltomaa (1994)
demonstrated that p53-positive bladder tumours show a signifi-
cantly higher number of apoptotic cells and bodies than p53-
negative tumours. In non-small-cell lung carcinomas, we found no
Table 5 Apoptotic indices and p53 expression
Apoptotic index (%)
Type of epithelium p53 status Mean Range Number of sections
Normal p53 – 0.34 0.00–0.69 14
p53 + 0
Squamous cell metaplasia p53 – 0.91 0.40–1.57 7
p53 + 1.00 1
Mild dysplasia p53 – 1.45 0.68–1.94 3
p53 + 0
Moderate dysplasia p53 – 1.45 0.18–4.40 6
p53 + 2.30 2.00–2.59 2
Severe dysplasia p53 – 1.13 0.52–1.62 4
p53 + 1.84 1.04–2.63 2
Carcinoma in situ p53 – 0
p53 + 1.49 0.63–3.26 5
Table 6 Apoptotic activity and the expression of bcl-2, mcl-1 and bax. Figures represent number of cases
Apoptotic activity
Normal and metaplastic tissue Premalignant tissue Total number of cases
≤0.74% >0.74% ≤0.74% >0.74%
bcl-2
Negative 4 3 0 7 14
Positive 13 2 4 10 29
mcl-l
Index ≤42 1 0 5 8
Index >4 8 0 3 6 17
bax
Index ≤43 0 1 6 1 0
Index>4 9 1 1 7 18Apoptosis in bronchial dysplasias 1001
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correlation between these two parameters (Törmänen et al, 1995).
In this study, both the apoptotic index and the degree of p53
protein accumulation increased with the severity of the dysplasia.
These strikingly different results on the relationship between p53
expression and apoptosis in different types of carcinoma empha-
size the need to study the effects of different mutations on the
apoptosis-regulating characteristics of the p53 gene. The study of
the expression of other apoptosis-regulating genes in different
tissues would also be of value because the lost ability of p53 to
induce apoptosis might be compensated by other, more powerful
regulators. One might also hypothesize that the elevation of the
apoptotic indices in bronchial dysplasias is due to a normal, apop-
tosis-promoting function of p53. In our opinion, this theory is
contradicted by the observation that the accumulation of immuno-
histochemically detectable p53 protein increased in parallel with
the severity of the dysplasia. The p53 protein in the lesions would
thus be mutated, or otherwise inactivated, and unable to induce
apoptosis.
The results of this study indicate that both the rate of cell prolif-
eration and the quantity of cell death are altered in parallel with the
morphological changes. We found a direct correlation between the
extent of apoptosis and the rate of cell proliferation, as evaluated
by PCNA immunohistochemistry. A similar association has been
previously shown in colorectal tubular and villous adenomas (Arai
and Kino, 1995) and carcinomas (Baretton et al, 1996), as well as
in gastric (Koshida et al, 1997), endometrial (Saegusa et al, 1996),
breast (Lipponen et al, 1994) and bladder (King et al, 1996)
carcinomas.
The expression of bcl-2 in this selection of normal bronchial
epithelium and dysplasias of different severity was quite similar to
that reported by Walker et al (1995). In our work, however, no
increase of bcl-2 expression could be seen as the severity of
dysplasia increased. Previously, we found no correlation between
the extent of apoptosis and the expression of bcl-2 in non-small-
cell lung carcinomas (Törmänen et al, 1995). Similarly, no associ-
ation between these two factors could be found in bronchial
dysplasias. Furthermore, no correlation was found between
apoptosis and the expression of bax and mcl-1.
The independence of apoptosis from the expression of p53 and
the bcl-2 family proteins suggests that the apoptotic signalling
pathway in bronchial dysplasias functions independently of these
factors. As it has been shown that the Fas receptor is expressed in
lung tumours (Hellquist et al, 1997), the main pathway leading to
apoptosis in bronchial dysplasias preceding SQCLC could also
include the activation of the Fas receptor. In this system, the Fas
ligand, bound for example to the cytotoxic lymphocytes, binds to
the oligomerized Fas receptor which then, via FADD-MORT,
activates FLICE (i.e. caspase 8) and, thus, the caspase cascade,
leading to apoptosis without the involvement of p53 and the bcl-2-
related proteins (Muzio et al, 1996; Nagata, 1997). This could
explain the independence of apoptosis from both the expression of
p53 and of the gene products of the bcl-2 family in bronchial
dysplasias and NSCLC.
Based on these results, it seems that the elevation of the apop-
totic index is an early event in the process in which the normal
bronchial epithelium changes to squamous cell carcinoma in situ,
and that the increase in the apoptotic activity is associated with the
severity of the bronchial premalignant lesion, i.e. dysplasia. The
highest apoptotic indices were found in severe dysplasias and
carcinoma in situ, exceeding even those reported for SQCLC in
our previous study (Törmänen et al, 1995). It is possible that the
high apoptotic activity in a premalignant lesion reflects an attempt
to eliminate genetically damaged cells and that, in the following
invasive carcinoma, the aggregated mutations somehow interfere
with the apoptosis-regulating mechanisms. In line with our obser-
vations, Birchall et al (1995) and Ishida et al (1996) have demon-
strated that the apoptotic activity is higher in premalignant gastric
lesions and in dysplasias of the oral cavity than in the corre-
sponding invasive carcinomas.
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